Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The conference call that might change your life forever!!!
2nd-QTR-$INNV-Innovus-Pharma-Earnings-and-CONF-Call-INFO-After-Close-8-14-18
Innovus Pharmaceuticals to Release Its Second Quarter 2018 Financial Results on Tuesday, August 14, 2018Press Release | 08/03/2018
Innovus Pharmaceuticals, Inc. (“Innovus Pharma”) (OTCQB: INNV) today announced that the Company will release its June 30, 2018 second quarter financial results on Tuesday, August 14, 2018, after the close of the U.S. financial markets. The Company will host a conference call at 4:15 p.m. ET/1:15 p.m. PT on the same day to discuss the financial results and recent business developments.
To participate in the call, please dial 1-877-883-0383 for domestic callers or 1-412-902-6506 for international callers or 1-877-885-0477 for Canadian callers and Participant Elite Entry Number: 0561047. A replay of the call will be available for 30 days. To access the replay, dial 1-877-344-7529 domestically or 1-412-317-0088 internationally or 1-855-669-9658 for Canada and reference Replay Access Code: 10123041. The replay will be available shortly after the end of the conference call.
https://www.otcmarkets.com/stock/INNV/news/Innovus-Pharmaceuticals-to-Release-Its-Second-Quarter-2018-Financial-Results-on-Tuesday-August-14-2018?id=199883 ;
The conference call that might change your life forever!!!
2nd-QTR-$INNV-Innovus-Pharma-Earnings-and-CONF-Call-INFO-After-Close-8-14-18
Innovus Pharmaceuticals to Release Its Second Quarter 2018 Financial Results on Tuesday, August 14, 2018Press Release | 08/03/2018
Innovus Pharmaceuticals, Inc. (“Innovus Pharma”) (OTCQB: INNV) today announced that the Company will release its June 30, 2018 second quarter financial results on Tuesday, August 14, 2018, after the close of the U.S. financial markets. The Company will host a conference call at 4:15 p.m. ET/1:15 p.m. PT on the same day to discuss the financial results and recent business developments.
To participate in the call, please dial 1-877-883-0383 for domestic callers or 1-412-902-6506 for international callers or 1-877-885-0477 for Canadian callers and Participant Elite Entry Number: 0561047. A replay of the call will be available for 30 days. To access the replay, dial 1-877-344-7529 domestically or 1-412-317-0088 internationally or 1-855-669-9658 for Canada and reference Replay Access Code: 10123041. The replay will be available shortly after the end of the conference call.
https://www.otcmarkets.com/stock/INNV/news/Innovus-Pharmaceuticals-to-Release-Its-Second-Quarter-2018-Financial-Results-on-Tuesday-August-14-2018?id=199883 ;
The conference call that might change your life forever!!!
2nd-QTR-$INNV-Innovus-Pharma-Earnings-and-CONF-Call-INFO-After-Close-8-14-18
Innovus Pharmaceuticals to Release Its Second Quarter 2018 Financial Results on Tuesday, August 14, 2018Press Release | 08/03/2018
Innovus Pharmaceuticals, Inc. (“Innovus Pharma”) (OTCQB: INNV) today announced that the Company will release its June 30, 2018 second quarter financial results on Tuesday, August 14, 2018, after the close of the U.S. financial markets. The Company will host a conference call at 4:15 p.m. ET/1:15 p.m. PT on the same day to discuss the financial results and recent business developments.
To participate in the call, please dial 1-877-883-0383 for domestic callers or 1-412-902-6506 for international callers or 1-877-885-0477 for Canadian callers and Participant Elite Entry Number: 0561047. A replay of the call will be available for 30 days. To access the replay, dial 1-877-344-7529 domestically or 1-412-317-0088 internationally or 1-855-669-9658 for Canada and reference Replay Access Code: 10123041. The replay will be available shortly after the end of the conference call.
https://www.otcmarkets.com/stock/INNV/news/Innovus-Pharmaceuticals-to-Release-Its-Second-Quarter-2018-Financial-Results-on-Tuesday-August-14-2018?id=199883 ;
The conference call that might change your life forever!!!
2nd-QTR-$INNV-Innovus-Pharma-Earnings-and-CONF-Call-INFO-After-Close-8-14-18
Innovus Pharmaceuticals to Release Its Second Quarter 2018 Financial Results on Tuesday, August 14, 2018Press Release | 08/03/2018
Innovus Pharmaceuticals, Inc. (“Innovus Pharma”) (OTCQB: INNV) today announced that the Company will release its June 30, 2018 second quarter financial results on Tuesday, August 14, 2018, after the close of the U.S. financial markets. The Company will host a conference call at 4:15 p.m. ET/1:15 p.m. PT on the same day to discuss the financial results and recent business developments.
To participate in the call, please dial 1-877-883-0383 for domestic callers or 1-412-902-6506 for international callers or 1-877-885-0477 for Canadian callers and Participant Elite Entry Number: 0561047. A replay of the call will be available for 30 days. To access the replay, dial 1-877-344-7529 domestically or 1-412-317-0088 internationally or 1-855-669-9658 for Canada and reference Replay Access Code: 10123041. The replay will be available shortly after the end of the conference call.
https://www.otcmarkets.com/stock/INNV/news/Innovus-Pharmaceuticals-to-Release-Its-Second-Quarter-2018-Financial-Results-on-Tuesday-August-14-2018?id=199883 ;
The conference call that might change your life forever!!!
2nd-QTR-$INNV-Innovus-Pharma-Earnings-and-CONF-Call-INFO-After-Close-8-14-18
Innovus Pharmaceuticals to Release Its Second Quarter 2018 Financial Results on Tuesday, August 14, 2018Press Release | 08/03/2018
Innovus Pharmaceuticals, Inc. (“Innovus Pharma”) (OTCQB: INNV) today announced that the Company will release its June 30, 2018 second quarter financial results on Tuesday, August 14, 2018, after the close of the U.S. financial markets. The Company will host a conference call at 4:15 p.m. ET/1:15 p.m. PT on the same day to discuss the financial results and recent business developments.
To participate in the call, please dial 1-877-883-0383 for domestic callers or 1-412-902-6506 for international callers or 1-877-885-0477 for Canadian callers and Participant Elite Entry Number: 0561047. A replay of the call will be available for 30 days. To access the replay, dial 1-877-344-7529 domestically or 1-412-317-0088 internationally or 1-855-669-9658 for Canada and reference Replay Access Code: 10123041. The replay will be available shortly after the end of the conference call.
https://www.otcmarkets.com/stock/INNV/news/Innovus-Pharmaceuticals-to-Release-Its-Second-Quarter-2018-Financial-Results-on-Tuesday-August-14-2018?id=199883 ;
This is the conference call that might change your life for ever!!
2nd-QTR-$INNV-Innovus-Pharma-Earnings-and-CONF-Call-INFO-After-Close-8-14-18
Innovus Pharmaceuticals to Release Its Second Quarter 2018 Financial Results on Tuesday, August 14, 2018Press Release | 08/03/2018
Innovus Pharmaceuticals, Inc. (“Innovus Pharma”) (OTCQB: INNV) today announced that the Company will release its June 30, 2018 second quarter financial results on Tuesday, August 14, 2018, after the close of the U.S. financial markets. The Company will host a conference call at 4:15 p.m. ET/1:15 p.m. PT on the same day to discuss the financial results and recent business developments.
To participate in the call, please dial 1-877-883-0383 for domestic callers or 1-412-902-6506 for international callers or 1-877-885-0477 for Canadian callers and Participant Elite Entry Number: 0561047. A replay of the call will be available for 30 days. To access the replay, dial 1-877-344-7529 domestically or 1-412-317-0088 internationally or 1-855-669-9658 for Canada and reference Replay Access Code: 10123041. The replay will be available shortly after the end of the conference call.
https://www.otcmarkets.com/stock/INNV/news/Innovus-Pharmaceuticals-to-Release-Its-Second-Quarter-2018-Financial-Results-on-Tuesday-August-14-2018?id=199883 ;
Can someone please post the info of tomorrow's conference call? I will make it rain over other forums tomorrow.
What do you think it's going to happen if we get every product of our line up inside of CVS? that's 10000 stores and online sales, how hard do you think it will be to get accepted by walgreens once we are in CVS? How hard do you think it would be for INNOVUS to go into the higiene and beauty sector where product rotation is way higher, think shampoo, soap, deodorant etc... I keep saying this over and over again, I believe ( and this is my opinion) we are buying the next johnson & johnson at 0.15 cents. Time will tell. It's 12:38 am already over here so I'll continue this conversation tomorrow. Good night.
anything we say here is pure speculation, however, the company is growing so fast and at so many fronts I wouldn't be sorprised if we get to the 4 dollar mark needed to uplist to nasdaq organically (based on revenues, company growth, expansion and obviously profitability) time will tell, but I love what I see!!!
I don't have access to a regular computer since I'm traveling, but at the cell version of td Ameritrade doesn't show the news.
I just did my friend but we need to make all the waves we can!!!
Guys, I have an idea and I need whoever is going to help to write "I'm in", here it is: the most active boards appear every day in a list we all have access to at the upper part of the investorshub under the tab "hot", a lot of investors pay attention to that list and specially if the stock that made the list has a newspaper icon next to the ticker(that means the stock is hot due to blockbuster news), the idea is to use all 15 posts we all have available next tuesday, that will take us into the list and once they check us out they will know what the fuzz is all about. I think we can attract a lot of new investors by doing it. Let's bring "all in" back into the board, he writes 3 posts per minute and thats exactly what we need.
Because only us know the news, TD ameritrade doesn't show anything, Innv needs to do a better job at advertising our achievements.
Let us get both feet in CVS and Europe and we will be ready.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 10, 2018
INNOVUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Nevada
000-52991
90-0814124
(State or other jurisdiction of incorporation)
(Commission
File Number)
(IRS Employer Identification No.)
8845 Rehco Road, San Diego, CA
92122
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number, including area code: (858) 249-7873
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
?
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
?
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
?
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
?
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
In this report, “Innovus Pharmaceuticals,” “Innovus Pharma,” “the Company”, “we,” “us” and “our” refer to Innovus Pharmaceuticals, Inc., and/or one or more of our wholly-owned subsidiaries, unless the context otherwise provides. Innovus Pharma® is a registered service mark of Innovus Pharmaceuticals, Inc.
Item 8.01 – Other Events
On August 10, 2018, the Company issued a press release announcing that it had entered into a purchase agreement with Showcase, a Canadian company for the purchase of its product Apeaz ® for sale in its 110 stores in the U.S. and Canada.
The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 -- Financial Statements and Exhibits
NEWS, NEWS, NEWS, WE ARE GETTING HUGE!!!!
what I'm going to say is just speculation, however you all know the recent developments make the following scenario very possible:
Imagine for a second the trial with Androferti at CVS is a success and they decide to introduce our full line of products into their stores how much are your stocks worth? 2 dollars? 5 dollars a piece? 10? selling a single share is just plain stupid right now, this is the moment every investor dreams off, it might be blast time baby!!!!
by the way, 53 billion are pfizer sales per year, however, they are only the 4th largest pharma company in the world, J&J sales north of 70B per year, Smith clain &glaxo, Bayern etc. 23 pharmaceutical companies sale over 10B dollars per year, who says we can't be next. I think getting in CVS could be the biggest milestone any pharmaceutical had to acchieve to get there and we have 1 foot in. if we get in prepare yourself for our first year above 100 million dollars and I believe that's a very conservative number.
Someone already took the time to compare INNV to Pfizer, a company 6000 times bigger in revenues, obviously we didn't win, but I believe someone is really afraid. The other conclusion about this article is the upside potential of this company is just unbelieveble, imagine us taking 5% of a 53 billion dollar business, that will be almost 3 billion dollars in sales.
https://www.fairfieldcurrent.com/2018/08/07/innovus-pharmaceuticals-innv-and-pfizer-pfe-head-to-head-survey.html
I'm in Europe with my family, we have a time diference of 6 hours compared to Florida and the east coast, what I will do is bombard those forums as soon as I weak up on the 14th, so my post is going to be the first thing they see when they wake up. Can't make any promeses on the rest of the day since I will be touristing Berlin and traveling to Vienna that day.
I think the best we can do is to stick to his words, if we get 6.6 million, great, that's within his range, if we get more, awesome!!!
The fundamentals of this company are shaping beautifuly, and is setting up the path for an unbelievable future. I really think the same way you do and many other members of the board, there's not a single company in the OTC market with this kind of revenue, this kind of growth and this kind of projection with a market value so low, but here is the good part, sooner or later the price always catches up. Be patiente, have a strategy, buy the deeps and wait, we are already making waves, the tsunami is coming and I'm planning to ride it all the way to FIJI.
Good morning my fellow investors, the great news about INNV just continue to pour in. Just relax, drink a cup of coffee and say to yourself "I knew I made a great investment".
S&P 5000.00%
DJIA0.00%
NASDAQ0.00%
TD Ameritrade Logo
menu
Select button to turn on accessible tables and lists.Accessibility on
Stock: Profile
INNV $0.1631
Innovus Pharmaceuticals, Inc. Common Stock (QB)
As of 3:59:40pm ET 8/6/2018
$0.00 (0.00%)
Watch List
1d
1 day 5d
5 days 1m
1 month 3m
3 months 6m
6 months 1y
1 year 3y
3 years
Use regions/landmarks to skip ahead to chart.
Chart
Long description.
No description available.
Structure.
Chart type: line chart.
line with 0 data points.
News Article
Innovus Pharma Announces Three Regulatory Filings with Health Canada for Its Products: Xyralid(R) Suppositories, Beyond Human(R) Testosterone and RecalMax(TM)
6:05am ET 8/7/2018 BusinessWire
Mentioned in article
INNV
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company") (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men's and women's health and respiratory diseases, today announced the filing by it for regulatory approval in Canada for its (1) Xyralid(R) Suppositories drug for the relief of hemorrhoidal swelling, (2) Beyond Human(R) Testosterone to promote and maintain testosterone levels in men and (3) RecalMax(TM) for cognitive health and mental sharpness. The regulatory approval process for the three products may take anywhere up to 210 days for approval depending on the application.
"We are happy to announce our filing of applications with Health Canada for our Xyralid(R) Suppositories, Beyond Human(R) Testosterone and RecalMax(TM)," said Dr. Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma. "We believe, if approved, these three products will sell well in Canada for their indications and will then represent the six, seventh and eighth products launched by us in Canada through our own sales and marketing commercial efforts in addition to our products ProtaGoRx(TM), Vesele(R), Apeaz(R), Xyralid(R) and AllerVarx(TM). When combined with the other four products we have launched there already through third-party distributors, including Zestra(R), Zestra Glide(R) and Uxor(R) (EjectDelay(R)) marketed by Orimed Pharma and UriVarx(R) through our partnership with Acerus Pharmaceuticals Corporation, we may have in total, in the near future, twelve of our products being marketed and sold in Canada."
About Xyralid(R) Suppositories
Xyralid(R) Suppositories was filed as an OTC drug in Canada with the indication to temporarily shrink hemorrhoidal tissue. Xyralid(R) Suppositories temporarily relieve itching, burning and discomfort associated with hemorrhoids and aid in protecting irritated anorectal areas.
About Beyond Human(R) Testosterone
Beyond Human(R) Testosterone is a patented product filed in Canada as a Natural Health Product with the indication to promote and maintain the levels of testosterone in men, which often decline with normal aging.
About RecalMax(TM)
RecalMax(TM) is a patented formulation of L-Arginine and L-Citrulline, in combination with the natural absorption enhancer Bioperine(R). RecalMax(TM) was filed in Canada as a Natural Health Product with the indication to increase mental health and mental sharpness. The beneficial effects of RecalMax(TM) on cognitive functions were confirmed in a four-month U.S. clinical survey study involving 152 patients (69 men and 83 women). Results from the clinical survey have indicated improvement in multiple brain functions, including word recall and focus.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly; (b) commercial partners to primary care physicians, urologists, gynecologists and therapists; and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application ("ANDA") products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.
For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; www.apeaz.com; www.diabasens.com; and www.xyralid.com.
Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from the potential three above products in Canada, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20180807005029r1&sid=cmtx6&distro=nx&lang=en
View source version on businesswire.com: https://www.businesswire.com/news/home/20180807005029/en/
SOURCE: Innovus Pharmaceuticals, Inc.
Innovus Pharma Investor Relations Randy Berholtz, +1-858-249-7865 ir@innovuspharma.com
Events
Earnings
Actual --
Est range -- to --
Comparisons
1d
1 day 5d
5 days 1m
1 month 3m
3 months 6m
6 months 1y
1 year 3y
3 years
INNV0.00%
Innovus Pharmaceuticals, Inc. Common Stock (QB)
$SPX.X0.00%
S&P 500 Index
Sector0.29%
Health Care
Industry0.03%
Pharmaceuticals
There is no peer information for INNV.
Guys, have you seen the amount of new MM showing up in level 2? we use to have 4 on a daily basis, sometimes 5 or 6, but the number is increasing, the word is getting out.
I'LL SEE YOU AT THE TOP!!!
JT, if what you say is true and we have grown so fast without Amazon sales THEN, you are bringing WONDERFUL NEWS to all the investors, it means we are growing at an unbeliebleble rate and we don't depend on third party to continue our growth, I sure hope you are right, THANK YOU FOR BRINGING THESE GREAT NEWS TO US ALL.
I'll see you at the top!!!
I just retweeted Innovus tweets and tagged #invest #investment #wallstreet #allergy #menshealth etc...
hell, it took me 2 minutes and I feel I made a contribution to MY company.
Our time has come guys, I can feel it.
MHO. Do your own DD.
IMHO Everybody is starting to realize the kind of stock they own and as word spreads out we are going to fly.
That's just my opinion, please do your own DD, but once you do, you more than likely will agree with me.
I love what this stock is doing, it seems like success is innevitable.
The break out is going to happen any day now, CNN Money, See thru equity and another mayor market analyst can't all be seeing the same thing based on nothing, every estimate is between $1.34 and $1.50, we have a 9 to 10 bagger in our hands.
That's a beautiful payday, no doubt about that, however I think Dr Da has created a monster of a company and he knows it, if he lets the recent developments mature then he can walk out with ten times that amount, let's think for a second, let's say things go well with androferti and CVS, then we will position our products in the largest Pharmaceutical chain in the world, do you think walgreens, Pill box and other pharma gigants don't want a piece of the pie? do you think if walmart sees good movement in online sales for fluti, urivarx, vessele, Xyralid etc they won't give ir a try at the stores? isn't Sam's and Walmart runned by the same people?... GUYS, THE SKY IS THE F%$#@ING LIMIT.
Congratulations my friend, that's the kind of stories I love to hear; hopefully in a few days you are going to be in other boards saying the same thing referring to a huge Innovus move up!!!
I'll see you at the top!!!
we have had days where we have traded 4 million shares, 25 million shares are nothing, bring them on, too many good news propelling this boat to be stoped by early profit takers.
You are forgetting they got the approval from Amazon to expand our product offer to Europe.
Insiders and everybody else, We all know, but for some unbelievable reason a lot of people are waiting until this stock gets to .50 cents to buy more... this belongs in replay's believe it or not.
I thought Fluticare was the magic product that was going to transform this company into a great company, Androferti seems to be the one that is going to open up Alibaba's treasure.
Hi Mynah, I can't compite with your son in education, he is an Ivy league graduate after all, but after analysing this stock for the last 6 months I believe he is part right and part wrong, it is speculative, since we don't know for sure if it's going to continue to grow (however, things are looking great) but the part we disagree is the high risk part. We have a stock selling tons of money and grabbing new customers daily with tons of patents, great customer base, products competing face to face mith multi billion dollar products, signing deals with the biggest retailers in the world and the current value is only 30 million dollars. I believe this stock has being de-risked. It's my opinion and I might not be an Ivy league, but I have hit a couple of slam dunks in the market and I see INNV as my next one.
I'll see you at the top!!!